GLP-1 Prior Authorization Denied? What to Do Next

AppealWise · Updated October 2026 · 7 min read

Whether it's Zepbound, Mounjaro, Ozempic, or Wegovy, a GLP-1 prior authorization denial hits the same wall: the plan's criteria, your documentation, or step therapy. The good news is the appeal path is nearly identical across all four drugs — and it works. Here's the playbook.

Why GLP-1 PAs get denied (the same 4 reasons)

1. Step therapy — the plan wants you to try a cheaper medication first and document the result.
2. Incomplete clinical documentation — labs, BMI, diagnosis, or prior-treatment records weren't attached. Most fixable denial.
3. Criteria not met on paper — the plan's clinical criteria (BMI threshold, comorbidity, A1c) exist but your chart didn't show them.
4. Formulary / coverage exclusion — the drug isn't on your plan's list; needs a medical-necessity formulary exception.

The 5-step appeal path

1. Decode the letter. Quote the denial reason word for word. It tells you exactly which bucket you're in.
2. Call the insurer. Ask what specific criteria you didn't meet and whether the PA policy is available. This costs 15 minutes and often reveals a simple documentation gap.
3. Get the doctor letter. One paragraph from your prescriber: diagnosis, BMI/comorbidities, what's been tried, why this drug. The single biggest success factor in GLP-1 appeals.
4. Build the packet. Cover letter + rebuttal of the exact reason + chart notes + doctor letter. Send to the appeals address on the denial notice, fax or certified mail, keep copies.
5. Escalate. Internal appeal (at least 180 days from denial date) → if denied, external review (free, binding on the insurer, usually within 4 months).

Drug-specific notes

• Ozempic / Mounjaro (type 2 diabetes indications) — A1c and diabetes documentation are the core evidence.
• Zepbound / Wegovy (weight management) — BMI history, comorbidity records, and prior weight-loss attempts matter most.